4564 — OncoTherapy Science Share Price
0.000.00%
Last trade - 00:00- ¥10bn
- ¥9bn
- ¥610m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 23.24 | ||
| Price to Tang. Book | 23.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 13.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -250.18% | ||
| Return on Equity | -213.12% | ||
| Operating Margin | -208.18% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 316.21 | 332.48 | 1,153.66 | 1,134.9 | 610.12 | n/a | n/a | 16.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.
Directors
- Kyoko Fujiya PRE (53)
- Suyoun Chung OTH (35)
- Takuya Tsunoda DRC (54)
- Hiroshi Yamaji DRC (53)
- Toyomasa Katagiri IND (47)
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- April 6th, 2001
- Public Since
- December 8th, 2003
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 256,843,679
- Address
- 1-2, Higashida-cho, Kawasaki-ku, KAWASAKI-SHI, 210-0005
- Web
- https://www.oncotherapy.co.jp/
- Phone
- +81 442016429
- Auditors
- Yamato Audit Corporation
Upcoming Events for 4564
OncoTherapy Science Inc Annual Shareholders Meeting
Q1 2025 OncoTherapy Science Inc Earnings Release
Q2 2025 OncoTherapy Science Inc Earnings Release
Similar to 4564
3-D Matrix
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics Co
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
Chiome Bioscience
Tokyo Stock Exchange
FAQ
What is the OncoTherapy Science share price?
As of Today at 22:29 UTC, shares in OncoTherapy Science are trading at ¥32. This share price information is delayed by 15 minutes.
How has the OncoTherapy Science share price performed this year?
Shares in OncoTherapy Science last closed at ¥32 and the price had moved by -23.81% over the past 365 days. In terms of relative price strength the OncoTherapy Science share price has underperformed the Nikkei 225 Index by -35.8% over the past year.
What are the analyst and broker recommendations for OncoTherapy Science?
There is no consensus recommendation for this security.
What is the OncoTherapy Science dividend yield?
OncoTherapy Science does not currently pay a dividend.
Does OncoTherapy Science pay a dividend?
OncoTherapy Science does not currently pay a dividend.
When does OncoTherapy Science next pay dividends?
OncoTherapy Science does not currently pay a dividend.
How do I buy OncoTherapy Science shares?
To buy shares in OncoTherapy Science you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of OncoTherapy Science?
As of the previous close price of ¥32, shares in OncoTherapy Science had a market capitalisation of ¥8bn.
Where are OncoTherapy Science shares listed?
Here are the trading details for OncoTherapy Science:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4564
What kind of share is OncoTherapy Science?
Based on an overall assessment of its quality, value and momentum OncoTherapy Science is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a OncoTherapy Science share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the OncoTherapy Science share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OncoTherapy Science. Over the past six months, its share price has outperformed the Nikkei 225 Index by +46.18%.
As of the last closing price of ¥32, shares in OncoTherapy Science were trading +35.77% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the OncoTherapy Science PE Ratio?
The OncoTherapy Science PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of OncoTherapy Science?
OncoTherapy Science's management team is headed by:
- Kyoko Fujiya - PRE
- Suyoun Chung - OTH
- Takuya Tsunoda - DRC
- Hiroshi Yamaji - DRC
- Toyomasa Katagiri - IND